| Elrexfio |
761345 |
001 |
351(a) |
elranatamab-bcmm |
Injection |
Subcutaneous |
76MG/1.9ML (40MG/ML) |
Single-Dose Vial |
2023/08/14
|
Pfizer Inc. |
Rx |
Licensed |
N/A |
N/A |
| Elrexfio |
761345 |
002 |
351(a) |
elranatamab-bcmm |
Injection |
Subcutaneous |
44MG/1.1ML (40MG/ML) |
Single-Dose Vial |
2023/08/14
|
Pfizer Inc. |
Rx |
Licensed |
N/A |
N/A |
| Talvey |
761342 |
001 |
351(a) |
talquetamab-tgvs |
Injection |
Subcutaneous |
3MG/1.5ML (2MG/ML) |
Single-Dose Vial |
2023/08/09
|
Janssen Biotech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Talvey |
761342 |
002 |
351(a) |
talquetamab-tgvs |
Injection |
Subcutaneous |
40MG/ML |
Single-Dose Vial |
2023/08/09
|
Janssen Biotech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Balfaxar |
125776 |
001 |
351(a) |
Prothrombin complex concentrate, human-lans |
For Injection |
Intravenous |
500IU |
Single-Dose Vial |
2023/07/21
|
Octapharma Pharmazeutika Produktionsges.m.b.H. |
Rx |
Licensed |
|
|
| Balfaxar |
125776 |
002 |
351(a) |
Prothrombin complex concentrate, human-lans |
For Injection |
Intravenous |
1000IU |
Single-Dose Vial |
2023/07/21
|
Octapharma Pharmazeutika Produktionsges.m.b.H. |
Rx |
Licensed |
|
|
| CYFENDUS |
125761 |
001 |
351(a) |
Anthrax Vaccine Adsorbed, Adjuvanted |
Injection |
Intramuscular |
100UG/ML |
Multi-Dose Vial |
2023/07/20
|
Emergent Product Development Gaithersburg, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Beyfortus |
761328 |
001 |
351(a) |
nirsevimab-alip |
Injection |
Intramuscular |
50MG/0.5ML |
Pre-Filled Syringe |
2023/07/17
|
Sanofi Pasteur Inc. |
Rx |
Licensed |
N/A |
N/A |
| Beyfortus |
761328 |
002 |
351(a) |
nirsevimab-alip |
Injection |
Intramuscular |
100MG/ML |
Pre-Filled Syringe |
2023/07/17
|
Sanofi Pasteur Inc. |
Rx |
Licensed |
N/A |
N/A |
| Roctavian |
125720 |
001 |
351(a) |
valoctocogene roxaparvovec-rvox |
Injection |
Intravenous |
16X 10E13GENOMES PER ML |
Single-Dose Vial |
2023/06/29
|
Biomarin Pharmaceutical Inc. |
Rx |
Licensed |
|
|
| Lantidra |
125734 |
001 |
351(a) |
donislecel-jujn |
Suspension |
Intravenous |
1X10E6EQUIVALENT ISLET NUMBER (EIN) |
Bag |
2023/06/28
|
CellTrans Inc. |
Rx |
Licensed |
|
|
| Ngenla |
761184 |
001 |
351(a) |
somatrogon-ghla |
Injection |
Subcutaneous |
24MG/1.2ML (20MG/ML) |
Autoinjector |
2023/06/27
|
Pfizer Ireland Pharmaceuticals |
Rx |
Licensed |
N/A |
N/A |
| Ngenla |
761184 |
002 |
351(a) |
somatrogon-ghla |
Injection |
Subcutaneous |
60MG/1.2ML (50MG/ML) |
Autoinjector |
2023/06/27
|
Pfizer Ireland Pharmaceuticals |
Rx |
Licensed |
N/A |
N/A |
| Rystiggo |
761286 |
001 |
351(a) |
rozanolixizumab-noli |
Injection |
Subcutaneous |
280MG/2ML (140MG/ML) |
Single-Dose Vial |
2023/06/26
|
UCB, Inc. |
Rx |
Licensed |
N/A |
N/A |
| ELEVIDYS |
125781 |
001 |
351(a) |
delandistrogene moxeparvovec-rokl |
Suspension |
Intravenous |
1.33 ×10E14 vector genomes (vg)/kg/bodyweight(bw) |
Single-Dose Vial |
2023/06/22
|
Sarepta Therapeutics, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Fiasp |
208751 |
004 |
351(a) |
insulin aspart |
Injection |
Subcutaneous |
160UNITS/1.6ML (100UNITS/ML) |
Multi-Dose Cartridge |
2023/06/21
|
Novo Nordisk Inc. |
Rx |
Licensed |
N/A |
N/A |
| Vyvgart Hytrulo |
761304 |
001 |
351(a) |
efgartigimod alfa and hyaluronidase-qvfc |
Injection |
Subcutaneous |
1,008MG/5.6ML; 11,200UNITS/5.6ML (180MG/2,000UNITS/ML) |
Single-Dose Vial |
2023/06/20
|
Argenx BV |
Rx |
Licensed |
N/A |
N/A |
| Columvi |
761309 |
001 |
351(a) |
glofitamab-gxbm |
Injection |
Intravenous |
2.5MG/2.5ML (1MG/ML) |
Single-Dose Vial |
2023/06/15
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Columvi |
761309 |
002 |
351(a) |
glofitamab-gxbm |
Injection |
Intravenous |
10MG/10ML (1MG/ML) |
Single-Dose Vial |
2023/06/15
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Gamifant |
761107 |
004 |
351(a) |
emapalumab-lzsg |
Injection |
Intravenous |
50MG/2ML (25MG/ML) |
Single-Dose Vial |
2023/06/07
|
Swedish Orphan Biovitrum AB (publ) |
Rx |
Licensed |
N/A |
N/A |